Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16622970 | 1.00 | MAPT (0.53) | MAPTMAOAPTGS1ALDH1A1MAPK1 | |
| SCHEMBL21757295 | 0.83 | MAPT (0.51) | MAPTMAOAPTGS1ALDH1A1MAPK1 | |
| SCHEMBL20840100 | 0.81 | KDM4E (0.47) | MAPTALDH1A1MAPK1KDM4ESMN1; SMN2 | |
| SCHEMBL13589883 | 0.81 | SLC6A2 (0.56) | MAOAPTGS1MAPK1MEN1KMT2A | |
| SCHEMBL7090303 | 0.81 | SCN4A (0.46) | MAOAPTGS1ALDH1A1MEN1KMT2A | |
| SCHEMBL11598862 | 0.80 | MAOA (0.69) | MAOAPTGS1MAPK1MEN1KMT2A | |
| SCHEMBL13212031 | 0.80 | MAOA (0.69) | MAOAPTGS1MAPK1MEN1KMT2A | |
| SCHEMBL940075 | 0.79 | MAPT (0.54) | MAPTALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL21749917 | 0.78 | MTNR1A (0.58) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL21749916 | 0.78 | MTNR1A (0.58) | MAPTALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227459-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-07-20 | — | — | US | disclosed |
| US-11667642-B2 | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227459-A1 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE | ADIPOR1, ADIPOR2, FABP4 | MAPT 3588/4885MAOA 307/4885PTGS1 1747/4885 |
| US-11667642-B2 | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine derivative | CBR3, DHPS, HRH4 | MAPT 4242/4885MAOA 138/4885PTGS1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.